The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
April 25th 2025
NCCN updates colon cancer guidelines, emphasizing testing for DPYD gene variants before initiating fluoropyrimidine-based chemotherapy.
C. Brooke Adams, PharmD, BCOP, discusses the evolving diagnostic criteria and management strategies for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in CAR T-cell therapy, highlighting advances in toxicity prevention and treatment selection.
Read More
The expanding role of real-world evidence in regulatory and health technology assessment (HTA) decision-making highlights its growing acceptance for supplementing clinical trial data, addressing evidence gaps, and informing treatment value, despite challenges in data quality, accessibility, and regulatory compliance.
Read More
In a Nod to Precision Oncology, the FDA Approves Revumenib
The approval marks a significant milestone in the treatment of a rare and aggressive subtype of acute leukemia.
Read More